HLB Life Science Co.,Ltd.

As of March 31, 2026, HLB Life Science Co.,Ltd. carries a market capitalization of 463.63B, placing it among publicly traded companies globally. Its enterprise value stands at 608.33B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, HLB Life Science Co.,Ltd. has 121.85M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 9.01, and the price-to-book ratio stands at 1.58.

These figures are as of March 31, 2026. The EV/Sales ratio of 11.81 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 608.33B versus a market cap of 463.63B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, HLB Life Science Co.,Ltd. maintains a current ratio of 0.55, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 55.81, indicating elevated leverage, while an interest coverage ratio of -1.32 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, HLB Life Science Co.,Ltd. posted a negative return on equity (ROE) of -15.91, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -10.17, reflecting losses generated across the asset base. The company generates approximately 295.20M in revenue per employee across its workforce of 174.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 8.19 indicates how many times HLB Life Science Co.,Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, HLB Life Science Co.,Ltd. recorded 356.70M in income tax expense. The company reported a pretax loss of -50.25B and -50.45B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, HLB Life Science Co.,Ltd.'s stock has declined approximately 9.17% over the past 52 weeks. The 50-day moving average sits at 3,127.60, while the 200-day moving average is 3,494.69.

Over the twelve months ended March 31, 2026, HLB Life Science Co.,Ltd. generated 51.51B in revenue and converted that into -50.45B in net income, yielding earnings per share of -414.95. EBITDA reached -16.23B, while operating income came in at -21.81B.

As of March 31, 2026, HLB Life Science Co.,Ltd. holds 19.75B in cash and equivalents against 164.07B in total debt, resulting in a net debt position of 146.93B. Total book value stands at 293.60B, with working capital of -58.41B providing operational flexibility.

HLB Life Science Co.,Ltd. produced -23.49B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -19.97B in capital expenditures, free cash flow totaled -43.47B - equivalent to -356.37 per share.

Over the twelve months ended March 31, 2026, HLB Life Science Co.,Ltd. posted a gross margin of -2.81, reflecting its pricing power and cost economics. The operating margin of -42.33 and net profit margin of -97.94 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -9.37: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -4.60, meaning HLB Life Science Co.,Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

HLB Life Science Co.,Ltd.'s most recent stock split took place on May 9, 2024 with a 393:416 split ratio.

As of March 31, 2026, HLB Life Science Co.,Ltd. has an Altman Z-Score of 0.95, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.